Navigation Links
Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
Date:7/25/2012

Newport, R.I., July 25, 2012 - Migraine can be a disabling neurological disorder, often aggravated by accompanying nausea. Stimulation of the acupoint PC6 Neiguan, an approach to controlling nausea adopted by traditional Chinese medicine, has never been documented by published clinical studies in medical literature for the control of migraine-related nausea, until now. Published in the May 2012 Neurological Sciences (journal of the Italian Neurological Society)*, "Acupressure in the control of migraine-associated nausea" is a clinical trial demonstrating that continuous stimulation of the acupoint PC6 Neiguan on the inner wrist, as provided by Sea-Band wristbands, showed statistically significant improvement in migraine-related nausea versus not using the wristbands.

Previous studies have demonstrated the efficacy of Sea-Band and its continual stimulation of the acupressure point PC6 for nausea relief due to motion sickness, postoperative nausea and chemotherapy-induced nausea. However, this May 2012 study is the first published research aimed at verifying that pressure applied to the acupoint PC6 with Sea-Band is effective at relieving nausea during migraine.

Migraine affects more than 29.5 million Americans, according to the National Headache Foundation, and is considered by the World Health Organization as the 19th leading cause of all years lived with disability for both males and females. Eight out of every 10 people in the U.S. who are diagnosed with migraine report experiencing nausea.

"This new research supports what millions of Sea-Band users already know; that the acupressure wristbands provide fast, consistent, drug-free relief for nausea associated with migraine headaches," commented Leonard Nihan, president, Sea-Band U.S. "We're pleased to have this published study to reinforce Sea-Band's efficacy to the scientific and medical communities."

The Italian study included 40 female patients suffering from migraine without aura, if nausea was always present as an accompanying symptomatology of their migraine. The patients were treated randomly for a total of six migraine attacks: three with the application of Sea-Band wristbands, which applies continual pressure to the PC6 acupoint (phase SB), and three without it (phase C).

The intensities of nausea at the onset at 30, 60, 120 and 240 minutes were evaluated on a scale from zero to 10. The values were always significantly lower in phase SB than in phase C. Also the number of patients who reported at least a 50 percent reduction in the nausea score was significantly higher in phase SB than in phase C at 30, 60 and 120 minutes. The average nausea scores dropped in the SB phase from 6.36 0.35 in T0, to 4.60 0.39 in T1, to 3.11 0.40 in T2, to 1.88 0.31 in T3 and to 0.92 0.22 in T4. At each time step taken into consideration after the application of the Sea-Band wristbands, there was a statistically significant improvement over the non-treated phases. Moreover, there were a high percentage of responders to the treatment: i.e. 46.8 percent at 60 minutes; 71.8 percent at 120 minutes; 84.3 percent at 240 minutes with a consistent response over time.


'/>"/>
Contact: Stephanie LaDue
sladue@rlapr.com
914-241-0086
Robin Leedy & Associates, Inc.
Source:Eurekalert

Related medicine news :

1. New CDC study on racial disparities in infant mortality published in Journal of Womens Health
2. Wound care meta-review draws firm conclusions from Cochrane published studies
3. New Anthropology and Archaeology Resources Published at Sciences Social Network
4. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
5. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
6. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
7. Access to clinical trials drives dramatic increases in survival from childhood cancer
8. Interactive personal health records increase clinical preventive services
9. University of Minnesota licenses Clinical Decision Support technology
10. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia
11. Clinical trial first to test heart drug regimen for Duchenne muscular dystrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign that ... an app that lets users make and share payments through a smart device. In ...
(Date:2/5/2016)... ... February 05, 2016 , ... Dr. Justin Scott and Dr. ... Annual No Cost Dental Day to individuals in need. The event is scheduled to ... No Cost Dental Day is to provide dental care to community members in need. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... In sleep, ... form as a dream. A hallmark feature of patients with eating disorders is significant ... The eating disorder behaviors and obsessions are regarded as maladaptive means for coping with ...
(Date:2/5/2016)... ... ... Calls Blacklist has just been updated by mobile app developer Vlad Lee. The ... known bugs within the app. Calls Blacklist allows its users to only have to ... their device’s battery power or memory. It provides a powerful call blocker that is ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
(Date:2/4/2016)... Feb. 4, 2016  Aethlon Medical, Inc. (Nasdaq: ... biofiltration devices to treat life-threatening diseases, today announced ... ended December 31, 2015. --> ... set forth in our last quarterly call, we ... our long-term objective to establish the Aethlon Hemopurifier® ...
Breaking Medicine Technology: